With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $176.92, representing a 20.98% upside. In a report released on December 11, Citi also maintained ...

Top Dividend Kings for long-term investing in 2024, including high-yielders and top-gain potentials across various sectors.

Although it was receiving revenue from eight products, royalties from Johnson & Johnson (JNJ) subsidiary Janssen’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Here are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks. The post These are the 5 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pharmaceutical company claims Cigna units worked with SaveOn and caused J&J to pay more than $100 million in copay assistance than it would have otherwise.

General Mills (NYSE:GIS) tracked higher in early Friday trading after Bank of America upgraded the food stock to a Buy rating ...